Press release
biocrea and Boehringer Ingelheim Conclude Asset Purchase Agreement
Radebeul, Germany, February 29, 2012 – biocrea today announced the completion of an asset purchase and licensing deal with Boehringer Ingelheim. Under the terms of the agreement, biocrea will receive an undisclosed payment and will transfer the exclusive global rights for certain research programs originating from its phosphodiesterase (PDE) platform to Boehringer Ingelheim. This includes biocrea´s PDE2 inhibitors and its most advanced compound BCA909.“This transaction marks a key milestone in the evolution of biocrea, which was created only about a year ago,” said Tom Kronbach, CEO of biocrea. ”Importantly, this deal demonstrates our ability to identify and validate disease-relevant novel mechanisms of action for which we create high-quality drug candidates. The proceeds from this agreement will allow us to implement our strategy to build a sustainable company over the next several years.”
###
About biocrea
biocrea creates first-in-class drugs for the treatment of debilitating CNS diseases. Among others, the team was involved in the discovery and development of the anticonvulsant retigabine. Previous collaborators of the biocrea team include GlaxoSmithKline, Wyeth and Pfizer.
Please visit www.biocrea.com
Dr. Tom Kronbach
CEO
biocrea GmbH
Meissner Strasse 191
01445 Radebeul
Germany
Tel.: +49 351 / 4043 3332
Fax: +49 351 / 4043 3216
tom.kronbach@biocrea.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release biocrea and Boehringer Ingelheim Conclude Asset Purchase Agreement here
News-ID: 212735 • Views: …
More Releases from biocrea GmbH
biocrea’s first-in-class PDE2 inhibitor demonstrates strong potential for the …
- Data on novel PDE2 inhibitor BCA909 presented at 24th ECNP Congress in Paris -
Radebeul, Germany, September 7, 2011 – biocrea, a biopharmaceutical company focusing on novel treatments for disorders of the central nervous system (CNS), to-day announced data on its innovative CNS-penetrating PDE2 inhibitor. The com-pound, which is code-named BCA909, was selected as a candidate for preclinical development earlier this year. It demonstrates strong potential for the treatment of…
biocrea acquires CNS pipeline and PDE inhibitor platform from Biotie Therapies C …
- New entity will be based in Radebeul, Germany -
Radebeul, Germany, November 4, 2010 – biocrea GmbH today announced further details about the newly incorporated company and its strategy going forward. As published on October 29, biocrea acquires the CNS pipeline and phosphodiesterase enzyme (PDE) inhibitor platform from Biotie Therapies Corp. (HSE: BTH1V; Turku, Finland).
The new company will be based in Radebeul, Germany. Dr. Thomas Kronbach, Biotie’s former Chief Scientific…
More Releases for Radebeul
Meet T3AI 4.0: The First-Ever All in one TYPO3 AI Extension by T3Planet
Hello TYPO3 Peoples! Get ready to experience the magic of TYPO3 AI right in your TYPO3 backend. T3Planet is happy to introduce the first-ever all-in-one TYPO3 AI Extension - T3AI 4.0
As AI has become a key part of many open-source CMS platforms, T3Planet has taken the initiative to bring this innovation to TYPO3. We first launched T3AI 1.0 on October 12th, 2023. Since then, we've continuously improved the extension,…
T3OpenAI - TYPO3 ChatGPT Extension: Transforming Content Management with AI-Powe …
T3OpenAI, a pioneer in TYPO3 development, is proud to introduce the groundbreaking TYPO3 ChatGPT Extension, revolutionizing content creation and optimization within the TYPO3 ecosystem. This innovative integration leverages the power of OpenAI's ChatGPT to provide feature-rich content assistance, making TYPO3 even smarter and more efficient.
Welcome to the Future of TYPO3 Content Management
T3OpenAI's ChatGPT Integration brings unprecedented capabilities to TYPO3 users, offering a virtual content assistant right within the TYPO3 backend.…
Vibration Instrument Market Bolstered by Emerging New Advancements, Says QYR | P …
"LOS ANGELES, United States: QY Research offers an encyclopedic study of the global Vibration Instrument market with holistic insights into vital factors and aspects that impact future market growth. The global Vibration Instrument market has been analyzed for the forecast period 2022-2028 and historical period 2017-2021. In order to help players to gain comprehensive understanding of the global Vibration Instrument market and its critical dynamics, the research study provides detailed…
Vibration Instrument Market In-Depth Analysis Of Competitive Landscape, Executiv …
"Market Summary
A newly published report titled “(Vibration Instrument Market)” by QY Research throws light on the industry dynamics and current and future trends that play a key role in determining the business expansion. The report also highlights the key driving factors and restraints that are impacting the growth. For a comprehensive understanding, the professionals have reviewed the regulatory scenario, market entry strategies, best industry practices, pricing strategy, technology landscape, and…
biocrea’s first-in-class PDE2 inhibitor demonstrates strong potential for the …
- Data on novel PDE2 inhibitor BCA909 presented at 24th ECNP Congress in Paris -
Radebeul, Germany, September 7, 2011 – biocrea, a biopharmaceutical company focusing on novel treatments for disorders of the central nervous system (CNS), to-day announced data on its innovative CNS-penetrating PDE2 inhibitor. The com-pound, which is code-named BCA909, was selected as a candidate for preclinical development earlier this year. It demonstrates strong potential for the treatment of…
biocrea acquires CNS pipeline and PDE inhibitor platform from Biotie Therapies C …
- New entity will be based in Radebeul, Germany -
Radebeul, Germany, November 4, 2010 – biocrea GmbH today announced further details about the newly incorporated company and its strategy going forward. As published on October 29, biocrea acquires the CNS pipeline and phosphodiesterase enzyme (PDE) inhibitor platform from Biotie Therapies Corp. (HSE: BTH1V; Turku, Finland).
The new company will be based in Radebeul, Germany. Dr. Thomas Kronbach, Biotie’s former Chief Scientific…
